


This listing of claims will replace all prior versions, and listings of claims in the application:

1    **Claim 1.**    (Previously presented) A compound having the formula:



4         $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are members independently selected from H, substituted or  
5        unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or  
6        unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or  
7        unsubstituted heteroaryl,  $OR^8$ ,  $NO_2$ , CN and halogen

9           R<sup>8</sup> is a member selected from H, substituted or unsubstituted alkyl,  
10           substituted or unsubstituted cycloalkyl and substituted or  
11           unsubstituted aryl;

2 R<sup>5</sup> is a member selected from H, substituted or unsubstituted alkyl, substituted or  
3 unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl,  
4 substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl,  
5 CN and C(O)R<sup>9</sup>

7         $R^9$  is a member selected from H, substituted or unsubstituted alkyl,  
8        substituted or unsubstituted cycloalkyl, substituted or unsubstituted  
9        heteroalkyl,  $NR^{10}R^{11}$  and  $OR^{11}$

Page 2 of 9


21  $R^{10}$  is a member selected from H, substituted or unsubstituted  
22 alkyl, substituted or unsubstituted cycloalkyl and  $OR^{12}$   
23 wherein  
24  $R^{12}$  is a member selected from H, substituted or  
25 unsubstituted alkyl, substituted or unsubstituted  
26 cycloalkyl and substituted or unsubstituted  
27 heteroalkyl;  
28  $R^{11}$  is a member selected from H,  $C(O)R^{13}$ , substituted or  
29 unsubstituted alkyl, substituted or unsubstituted cycloalkyl,  
30 substituted or unsubstituted heteroalkyl, substituted or  
31 unsubstituted heterocycloalkyl, and substituted or  
32 unsubstituted aryl, and wherein  $R^{10}$  and  $R^{11}$ , together with  
33 the nitrogen to which they are bound, are optionally joined  
34 to form a substituted or unsubstituted heterocycloalkyl ring  
35 system having from 3 to 7 members  
36 wherein  
37  $R^{13}$  is a member selected from H, substituted or  
38 unsubstituted alkyl, substituted or unsubstituted  
39 cycloalkyl, substituted or unsubstituted heteroalkyl  
40 and  $NR^{14}R^{15}$   
41 wherein  
42  $R^{14}$  and  $R^{15}$  are members independently selected  
43 from H, substituted or unsubstituted alkyl  
44 and substituted or unsubstituted heteroalkyl;  
45  $R^6$  is a member selected from substituted alkyl, substituted and unsubstituted  
46 heteroalkyl, CN, substituted or unsubstituted aryl, substituted or  
47 unsubstituted heteroaryl and  $C(O)R^{16}$   
48 wherein  
49  $R^{16}$  is a member selected from substituted or unsubstituted alkyl,  
50 substituted or unsubstituted heteroalkyl, substituted or

51 unsubstituted aryl, substituted or unsubstituted heteroaryl,  $\text{NR}^{17}\text{R}^{18}$   
52 and  $\text{OR}^{17}$   
53 wherein  
54  $\text{R}^{17}$  and  $\text{R}^{18}$  are members independently selected from H,  
55 substituted or unsubstituted alkyl, substituted or  
56 unsubstituted heteroalkyl and substituted or unsubstituted  
57 aryl, and wherein  $\text{R}^{10}$  and  $\text{R}^{11}$ , together with the nitrogen to  
58 which they are bound, are optionally joined to form a  
59 heterocycloalkyl ring system having from 3 to 7 members;  
60  $\text{R}^7$  is a member selected from H, substituted or unsubstituted alkyl and substituted  
61 or unsubstituted heteroalkyl.

1 **Claim 2.** (Previously presented) The compound according to claim 1, wherein at  
2 least one of  $\text{R}^{10}$  and  $\text{R}^{11}$  is substituted or unsubstituted  $\text{C}_1\text{-C}_6$  alkyl.

1 **Claim 3.** (Previously presented) The compound according to claim 1, wherein  $\text{R}^5$  is  
2 a member selected from substituted or unsubstituted  $\text{C}_1\text{-C}_6$  alkyl, substituted or  
3 unsubstituted  $\text{C}_1\text{-C}_6$  heteroalkyl, substituted or unsubstituted  $\text{C}_1\text{-C}_6$  cycloalkyl and  
4 substituted or unsubstituted  $\text{C}_1\text{-C}_6$  heterocycloalkyl.

1 **Claim 4.** (Previously presented) The compound according to claim 1, having the  
2 formula:



1 **Claim 5.** (Cancelled)

1 **Claim 6.** (Previously presented) The compound according to claim 4, wherein  $\text{R}^5$  is  
2 selected from substituted or unsubstituted  $\text{C}_1\text{-C}_6$  alkyl and substituted or unsubstituted  
3  $\text{C}_1\text{-C}_6$  cycloalkyl.

1   **Claim 7.**       (Previously presented) The compound according to claim 4, wherein R<sup>3</sup> is  
2   halogen.

1   **Claim 8.**       (Previously presented) A pharmaceutical formulation comprising a  
2   compound according to claim 1 and a pharmaceutically acceptable carrier.

1   **Claim 9.**       (Withdrawn) A method of inhibiting HIV in a cell, said method  
2   comprising contacting said cell with an amount of a compound according to claim 1  
3   sufficient to inhibit said HIV.

1   **Claim 10.**     (Withdrawn) The method according to claim 9, wherein said HIV is a  
2   drug resistant mutant.

1   **Claim 11.**     (Withdrawn) A method of inhibiting reverse transcriptase in a cell, said  
2   method comprising contacting said cell with an amount of a compound according to  
3   claim 1 sufficient to inhibit said reverse transcriptase.

1   **Claim 12.**     (Withdrawn) The method according to claim 9, wherein said cell is in a  
2   human.

1   **Claim 13.**     (Withdrawn) The method according to claim 10, wherein said cell is in a  
2   human.

1   **Claim 14.**     (Withdrawn) A method of treating HIV infection in a human subject  
2   comprising administering to said subject an amount of a compound according to claim 1,  
3   sufficient to treat said HIV infection.

1   **Claim 15.**     (Withdrawn) The method according to claim 14, wherein said HIV is a  
2   drug resistant mutant.

1   **Claim 16.**     (Withdrawn) A method of providing prophylaxis against HIV infection  
2   comprising administering a prophylactic amount of a compound according to claim 1 to a  
3   person who is at risk of HIV infection.

1   **Claim 17.**     (Withdrawn) The method according to claim 13, wherein said HIV is a  
2   drug resistant mutant.

1   **Claim 18.**     (Previously presented) The compound according to claim 1, wherein R<sup>6</sup> is  
2   a member selected from substituted and unsubstituted ether, substituted and unsubstituted  
3   polyether, -CH<sub>2</sub>OH, and -CH<sub>2</sub>OC(O)CH<sub>3</sub>.